Relapse-free survival. (A) RFS was calculated relative to the date of bone marrow aspiration when CR was detected for the first time to the event date (date of the bone marrow aspiration at which hematologic relapse was first detected, the date of the diagnosis on which the hematologic or extramedullary relapse was documented, or the date of death because of any cause, whichever occurred earlier). (B) RFS was analyzed according to MRD response using the Kaplan-Meier method. (C) RFS was analyzed according to alloHSCT status after blinatumomab using a Simon-Makuch 71-day landmark analysis..